Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells

Background: Various studies have demonstrated that interleukin-6 (IL-6) activates the central magnocellular arginine vasopressin (AVP)-secreting neurons in the brain to produce non-osmotic, non-volume-mediated increases in AVP. The most common toxicity of CD19+ chimeric antigen receptor (CAR) T-cells is cytokine release syndrome, which is related to increased levels of IL-6. This study will evaluate the correlation of IL-6 levels with hyponatremia in patients receiving CD19+ CAR T-cells. Materials and methods: This is a single-center retrospective analysis of adult patients who received CD19+ CAR T-cells for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Results: Hyponatremia, defined as a serum sodium (Na) ≤ 135 mEq/L, occurred in 31 (61%) patients. A change in Na > 7 mEq occurred in 32 (63%) patients, and the median lowest Na was 133 mEq/L (interquartile range (IQR): 131 – 136)). There was an inverse linear relationship between IL-6 levels and lowest Na (p = 0.001). Overall, per 10-fold increase in IL-6, Na decreased by an average of 2.68 mEq/L. Conclusion: Hyponatremia is common in patients who received CD19+ CAR T-cells. There is an inverse linear relationship between IL-6 levels and nadir Na (p = 0.001). Further studies will be needed to confirm a causative relationship between IL-6 levels and hyponatremia following CD19+ CAR T-cell infusion.

[1]  R. Pazdur,et al.  FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome , 2018, The oncologist.

[2]  Daniel Li,et al.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.

[3]  M. Geyer,et al.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. , 2016, Blood.

[4]  T. Hew-Butler,et al.  Incidence of Exercise-Associated Hyponatremia and Its Association With Nonosmotic Stimuli of Arginine Vasopressin in the GNW100s Ultra-endurance Marathon , 2015, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[5]  A. Amin,et al.  Current treatment practice and outcomes. Report of the hyponatremia registry , 2015, Kidney international.

[6]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[7]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[8]  J. Herman,et al.  Stress activation of IL-6 neurons in the hypothalamus. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[9]  A. Nadjar,et al.  Interleukin-6 activates arginine vasopressin neurons in the supraoptic nucleus during immune challenge in rats. , 2009, American journal of physiology. Endocrinology and metabolism.

[10]  M. Moustaki,et al.  Hypothalamic-Pituitary-Adrenal Axis and Interleukin-6 Activity in Children with Head Trauma and Syndrome of Inappropriate Secretion of Antidiuretic Hormone , 2003, Journal of pediatric endocrinology & metabolism : JPEM.

[11]  R. Walker,et al.  Cyclophosphamide induced hemorrhagic cystitis. , 1999, The Journal of urology.

[12]  G. Chrousos,et al.  Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. , 1994, The Journal of clinical endocrinology and metabolism.

[13]  T. Stillwell,et al.  Cyclophosphamide‐induced hemorrhagic cystitis: A review of 100 patients , 1988, Cancer.

[14]  V. Devita,et al.  Clinical pharmacology of cyclophosphamide. , 1973, Cancer research.